Jefferies says buy this pharmaceutical play, sees more than 100% upside from here

By CNBC   |   1 year ago
Jefferies says buy this pharmaceutical play, sees more than 100% upside from here

Jefferies analysts see potential for Aclaris Therapeutics' stock to rise further due to recent drug developments. Positive results from BSI-045B treatment for atopic dermatitis could lead to significant gains, with other analysts also bullish on the company's prospects.

Read More

Did you find this insightful?